hERG activators exhibit antitumor effects in breast cancer through calcineurin and β-catenin-mediated signaling pathways
BackgroundBreast cancer remains a leading cause of mortality among women worldwide, with existing therapeutic options often accompanied by significant side effects and a persistent risk of disease recurrence. This highlights the need for novel drug candidates with new mechanisms of action by targeti...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1545300/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590811707998208 |
|---|---|
| author | Yan Yu Chengchun Zhu Xiao Wang Ying Shi Yiping Gao Zhiyi Yu |
| author_facet | Yan Yu Chengchun Zhu Xiao Wang Ying Shi Yiping Gao Zhiyi Yu |
| author_sort | Yan Yu |
| collection | DOAJ |
| description | BackgroundBreast cancer remains a leading cause of mortality among women worldwide, with existing therapeutic options often accompanied by significant side effects and a persistent risk of disease recurrence. This highlights the need for novel drug candidates with new mechanisms of action by targeting alternative signaling pathways. While hERG channel is notoriously regarded as an off-target due to drug-induced cardiotoxicity, its therapeutic potential as a drug target remains largely unexplored.MethodsThis study investigated the role of hERG in breast cancer progression and its impact on patient survival. The anti-proliferative, anti-migratory, anti-invasive and pro-apoptotic effects of hERG activators were evaluated using the Cell Counting Kit-8, wound healing assay, transwell assay and cell apoptosis assay, respectively. Western blotting, Ca2+ imaging and immunofluorescence assays were employed to study their antitumor mechanisms of actions.ResultsWe identified two novel hERG activators, SDUY429 and SDUY436, which effectively inhibited the proliferation and migration of MDA-MB-231 and MCF-7 cells. In addition, SDUY436 demonstrated significant anti-invasive and pro-apoptotic effects in MDA-MB-231 cells. Mechanistically, the anti-proliferative activity of hERG activators were mediated through calcineurin activation via enhanced calcium ion influx, which facilitated the nuclear translocation of nuclear factor of activated T cells (NFAT) and upregulated p21Waf/Cip expression. Furthermore, both SDUY429 and SDUY436 remarkably suppressed the migration and invasion of MDA-MB-231 cells by downregulating the protein kinase B (AKT)/glycogen synthase kinase-3 beta (GSK3β)/β-catenin signaling pathway. The observed reduction in phospho-AKT-Ser473 (pAKTS473) expression resulted in the decreased levels of phospho-GSK3β-Ser9 (pGSK3βS9), thereby limiting the nuclear localization of β-catenin, which led to the inhibition of cell migration and invasion. Notably, combining SDUY429 or SDUY436 with the AKT inhibitor MK-2206 produced synergistic anti-proliferative effects.ConclusionThese findings suggest that hERG activators hold promise as new potential therapeutic agents for the treatment of breast cancer, paving the way for future investigations into their clinical applications. |
| format | Article |
| id | doaj-art-51723e6b8dfe4572a3f82b091caf3681 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-51723e6b8dfe4572a3f82b091caf36812025-01-23T06:56:43ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011610.3389/fphar.2025.15453001545300hERG activators exhibit antitumor effects in breast cancer through calcineurin and β-catenin-mediated signaling pathwaysYan YuChengchun ZhuXiao WangYing ShiYiping GaoZhiyi YuBackgroundBreast cancer remains a leading cause of mortality among women worldwide, with existing therapeutic options often accompanied by significant side effects and a persistent risk of disease recurrence. This highlights the need for novel drug candidates with new mechanisms of action by targeting alternative signaling pathways. While hERG channel is notoriously regarded as an off-target due to drug-induced cardiotoxicity, its therapeutic potential as a drug target remains largely unexplored.MethodsThis study investigated the role of hERG in breast cancer progression and its impact on patient survival. The anti-proliferative, anti-migratory, anti-invasive and pro-apoptotic effects of hERG activators were evaluated using the Cell Counting Kit-8, wound healing assay, transwell assay and cell apoptosis assay, respectively. Western blotting, Ca2+ imaging and immunofluorescence assays were employed to study their antitumor mechanisms of actions.ResultsWe identified two novel hERG activators, SDUY429 and SDUY436, which effectively inhibited the proliferation and migration of MDA-MB-231 and MCF-7 cells. In addition, SDUY436 demonstrated significant anti-invasive and pro-apoptotic effects in MDA-MB-231 cells. Mechanistically, the anti-proliferative activity of hERG activators were mediated through calcineurin activation via enhanced calcium ion influx, which facilitated the nuclear translocation of nuclear factor of activated T cells (NFAT) and upregulated p21Waf/Cip expression. Furthermore, both SDUY429 and SDUY436 remarkably suppressed the migration and invasion of MDA-MB-231 cells by downregulating the protein kinase B (AKT)/glycogen synthase kinase-3 beta (GSK3β)/β-catenin signaling pathway. The observed reduction in phospho-AKT-Ser473 (pAKTS473) expression resulted in the decreased levels of phospho-GSK3β-Ser9 (pGSK3βS9), thereby limiting the nuclear localization of β-catenin, which led to the inhibition of cell migration and invasion. Notably, combining SDUY429 or SDUY436 with the AKT inhibitor MK-2206 produced synergistic anti-proliferative effects.ConclusionThese findings suggest that hERG activators hold promise as new potential therapeutic agents for the treatment of breast cancer, paving the way for future investigations into their clinical applications.https://www.frontiersin.org/articles/10.3389/fphar.2025.1545300/fullhERG activatorantitumor mechanismstriple negative breast cancerER+ breast cancercombination therapy |
| spellingShingle | Yan Yu Chengchun Zhu Xiao Wang Ying Shi Yiping Gao Zhiyi Yu hERG activators exhibit antitumor effects in breast cancer through calcineurin and β-catenin-mediated signaling pathways Frontiers in Pharmacology hERG activator antitumor mechanisms triple negative breast cancer ER+ breast cancer combination therapy |
| title | hERG activators exhibit antitumor effects in breast cancer through calcineurin and β-catenin-mediated signaling pathways |
| title_full | hERG activators exhibit antitumor effects in breast cancer through calcineurin and β-catenin-mediated signaling pathways |
| title_fullStr | hERG activators exhibit antitumor effects in breast cancer through calcineurin and β-catenin-mediated signaling pathways |
| title_full_unstemmed | hERG activators exhibit antitumor effects in breast cancer through calcineurin and β-catenin-mediated signaling pathways |
| title_short | hERG activators exhibit antitumor effects in breast cancer through calcineurin and β-catenin-mediated signaling pathways |
| title_sort | herg activators exhibit antitumor effects in breast cancer through calcineurin and β catenin mediated signaling pathways |
| topic | hERG activator antitumor mechanisms triple negative breast cancer ER+ breast cancer combination therapy |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1545300/full |
| work_keys_str_mv | AT yanyu hergactivatorsexhibitantitumoreffectsinbreastcancerthroughcalcineurinandbcateninmediatedsignalingpathways AT chengchunzhu hergactivatorsexhibitantitumoreffectsinbreastcancerthroughcalcineurinandbcateninmediatedsignalingpathways AT xiaowang hergactivatorsexhibitantitumoreffectsinbreastcancerthroughcalcineurinandbcateninmediatedsignalingpathways AT yingshi hergactivatorsexhibitantitumoreffectsinbreastcancerthroughcalcineurinandbcateninmediatedsignalingpathways AT yipinggao hergactivatorsexhibitantitumoreffectsinbreastcancerthroughcalcineurinandbcateninmediatedsignalingpathways AT zhiyiyu hergactivatorsexhibitantitumoreffectsinbreastcancerthroughcalcineurinandbcateninmediatedsignalingpathways |